Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
INBS Intelligent Bio Solutions Inc
BLNK Blink Charging Co
PYOIF Promotora y Operadora de Infraestructura SAB de CV
PZZA Papa John's International Inc
HOLI Hollysys Automation Technologies Ltd
Go

Health Care : Pharmaceuticals |
Based in Canada
Company profile

Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.

Closing Price
$0.3569
Day's Change
-0.008 (-2.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.38
Day's Low
0.345
Volume
(Heavy Day)
Volume:
1,243,334

10-day average volume:
911,172
1,243,334

Company Profile

Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.38x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
3.3M
Previous Month
3.0M
Percent of Float
2.25%
Days to Cover
3.1784 Days

Share Information

CYBN is in a share class of common stock
Float
147.8M
Shares Outstanding
185.2M
Institutions Holding Shares
57
10.28%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

  • 100 King Street West, Suite 5600
  • Toronto, ON M5X 1C9
  • Canada
  • Phone: 6048060626
  • Fax: 6048060626
  • https://www.cybin.com

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.